Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: Hepatic and gastric first- pass effects

Drug Metabolism and Disposition

Volumn 27, Issue 2, 1999, Pages 221-226

  Han, Kye S ^a   Lee, Myung G ^a   Lee, ^b  

^a Seoul National University   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (ALLYLTHIO)PYRAZINE; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TISSUE LEVEL; FIRST PASS EFFECT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DUODENUM; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; LIVER; MALE; PORTAL VEIN; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; STOMACH; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0032936690     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chiou WL (1978) Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
2. Chiou WL (1979) New calculation method for mean apparent drug volume of distribution and application to rationale dosage regimen. J Pharm Sci 68:1067-1069.
3. Chiou WL (1980) New calculation method of mean total body clearance of drugs and its application to rationale regimens. J Pharm Sci 69:90-91.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 7:1093-1095.
5. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L. Moore JD, Gibaldi M and Kaplan SA (1977) Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
6. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed., Dekker, New York.
7. Haber PS, Gentry RT, Mak KM, Mirmiran Yazdy SA, Greenstein RJ and Liber CS (1996) Metabolism of alcohol by human gastric cells: Relation to first-pass metabolism. Gastroenterology 111:863-870.
8. Han KS, Woo S-J, Koo CH and Lee MG (1998) Determination of a chemoprotective agent, 2-(allylthio)pyrazine, in plasma, urine and tissue homogenates by high-performance liquid chromatography. J Chromatogr B 710:239-242.
9. Huang SM, Huang YC and Chiou WL (1981) Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. J Pharmacokinet Biopharm 9:725-738.
10. Kim JH, Kim SH and Lee MG (1997a) Liver and gastrointestinal first-pass effect of azosemide in rats. J Pharm Pharmacol 49:878-883.
11. Kim ND, Kwak MK and Kim SG (1997b) Inhibition of cytochrome P450 2E1 expression by 2-(allylthio)pyrazine, a potential chemoprotective agent: Hepatoprotective effects. Biochem Pharmacol 53:261-269.
12. x-174 DNA strand breakage. Yakhak Hoeji 40:727-733.
13. Kim SH, Choi YM and Lee MG( 1993) Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
14. Kwak MK, Lee WI. Kim ND and Lee MG (1998) Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. Biopharm Drug Dispos 19:273-277.
15. Lee MG and Chiou WL (1983) Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
16. Lee SH and Lee MG (1995) Stability, tissue metabolism, tissue distribution and blood partition of azosemide. Biopharm Drug Dispos 16:547-561.
17. Lee SH and Lee MG (1996) Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats: Absorption from various GI segments. J Pharmacokinet Biopharm 24:551-568.
18. Litterst CL, Mimnaugh EG, Reagan RI and Gram TE (1975) Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 3:259-265.
19. Nam SY (1998) Molecular pharmacological studies on the radioactive mechanisms and the effects of radioprotective agents: The role of epoxide hydrolase and glutathione S-transferase expression. Ph.D. Thesis, Duksung Women's University, Seoul, South Korea.
20. Surh Y-J, Park KK, Kim SG, Sohn Y, Kim ND, Liem A and Miller JA (1997) Chemoprevention of vinyl carbamate- or vinyl carbamate epoxide-induced hepatotoxicity, mutagenicity, and tumorigenicity by 2-(allylthio)pyrazine. Proc Am Assoc Cancer Res 38:370.
21. Yoon WH, Yoo JK, Lee JW, Shim C-K and Lee MG (1998) Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7 after intravenous and oral administration to rats, rabbits, and dogs. Drug Metab Dispos 26:152-163.
22. Xu Z-X, Tang J-P, Badr M and Melethil S (1992) Kinetics of aluminum in rats: Effect of route of administration. J Pharm Sci 81:160-163.